You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

 

CME / ABIM MOC

Testing Your Knowledge of Oral Selective Estrogen Receptor Degraders

  • Authors: Mafalda Oliveira, MD, PhD
  • CME / ABIM MOC Released: 7/28/2023
  • Valid for credit through: 7/28/2024, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.25 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for oncologists, obstetricians/gynecologists, pathologists, and other clinicians who care for patients with breast cancer.

The goal of this activity is for learners to be better able to recognize the role of oral SERDs in advanced breast cancer care and identify ways to best incorporate oral SERDs into their clinical practice.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Mechanism of action of oral SERDs in hormone receptor (HR)-positive breast cancer 
    • Clinical data associated with the oral SERDs in HR-positive breast cancer
  • Self-assess learning needs related to
    • Incorporating oral SERDs into the treatment toolbox for patients with HR-positive metastatic breast cancer


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Mafalda Oliveira, MD, PhD

    Senior Consultant, Medical Oncology Department
    Vall d’Hebron University Hospital
    Senior Clinical Investigator, Breast Cancer Group
    Vall d’Hebron Institute of Oncology (VHIO)
    Vall d’Hebron Barcelona Hospital Campus
    Barcelona, Spain

    Disclosures

    Mafalda Oliveira, MD, PhD, has the following relevant financial relationships: 
    Consultant or advisor for: AstraZeneca Pharmaceuticals LP; Daiichi Sankyo, Inc.; Gilead Sciences, Inc.; iTeos Therapeutics; Merck Sharp & Dohme, Corp.; Pierre Fabre; Relay; Roche; Seagen, Inc.
    Speaker or member of speakers bureau for: AstraZeneca Pharmaceuticals LP; Eisai Inc.; Gilead Sciences, Inc.; Merck Sharp & Dohme, Corp.; Novartis; Pfizer, Inc.; Roche; Seagen, Inc.
    Research funding from: AstraZeneca Pharmaceuticals LP; Ayala Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Genentech; Gilead Sciences, Inc.; GlaxoSmithKline; Novartis; Roche; Seagen, Inc.; Zenith Epigenetics

Editors

  • Victoria Phoenix

    Medical Education Director, Medscape, LLC

    Disclosures

    Victoria Phoenix has no relevant financial relationships.

  • Tristin Abair, PhD

    Senior Medical Writer, Medscape, LLC

    Disclosures

    Tristin Abair, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Leigh Schmidt, MSN, RN, CNE, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.

    Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read about the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or print it out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Testing Your Knowledge of Oral Selective Estrogen Receptor Degraders

Authors: Mafalda Oliveira, MD, PhDFaculty and Disclosures

CME / ABIM MOC Released: 7/28/2023

Valid for credit through: 7/28/2024, 11:59 PM EST

processing....

The goals of continuing medical education (CME) and professional development are to acquire and retain knowledge that will enhance clinical practice and improve patient outcomes. The following self-assessment survey is offered for CME credit and is designed to test your current knowledge and skills related to the use of oral selection estrogen receptor degraders (SERDs) in the treatment of patients with hormone receptor (HR)-positive advanced breast cancer (ABC).

  • Print